Alnylam Pharmaceuticals
ALNY
#649
Rank
โ‚น2.607 T
Marketcap
โ‚น20,219
Share price
-7.14%
Change (1 day)
43.33%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚น15.6 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น2.09 Billion. In 2023 the company made an earning of -โ‚น26.37 Billion, an increase over its 2022 earnings that were of -โ‚น81.98 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚น15.6 Billion-40.85%
2023 -โ‚น26.37 Billion-67.84%
2022 -โ‚น81.98 Billion36.93%
2021 -โ‚น59.87 Billion-8.04%
2020 -โ‚น65.1 Billion-15.66%
2019 -โ‚น77.19 Billion12.23%
2018 -โ‚น68.78 Billion62.91%
2017 -โ‚น42.22 Billion17.78%
2016 -โ‚น35.85 Billion43.44%
2015 -โ‚น24.99 Billion60.69%
2014 -โ‚น15.56 Billion98.2%
2013 -โ‚น7.85 Billion
2011 -โ‚น4.63 Billion27.48%
2010 -โ‚น3.64 Billion-10.92%
2009 -โ‚น4.08 Billion95.77%
2008 -โ‚น2.09 Billion
2006 -โ‚น3.34 Billion-9.13%
2005 -โ‚น3.67 Billion34.74%
2004 -โ‚น2.73 Billion36.79%
2003 -โ‚น2 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น44.38 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น419.51 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.25 B-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น20.66 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น2.96 Billion-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.074 T-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น625.36 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น69.81 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel